Castillo, D.R.; Jeon, W.J.; Park, D.; Pham, B.; Yang, C.; Joung, B.; Moon, J.H.; Lee, J.; Chong, E.G.; Park, K.; Reeves, M.E.; Duerksen-Hughes, P.; Mirshahidi, H.R.; Mirshahidi, S. Comprehensive Review: Unveiling the Pro-Oncogenic Roles of IL-1ß and PD-1/PD-L1 in NSCLC Development and Targeting Their Pathways for Clinical Management. Int. J. Mol. Sci.2023, 24, 11547.
Castillo, D.R.; Jeon, W.J.; Park, D.; Pham, B.; Yang, C.; Joung, B.; Moon, J.H.; Lee, J.; Chong, E.G.; Park, K.; Reeves, M.E.; Duerksen-Hughes, P.; Mirshahidi, H.R.; Mirshahidi, S. Comprehensive Review: Unveiling the Pro-Oncogenic Roles of IL-1ß and PD-1/PD-L1 in NSCLC Development and Targeting Their Pathways for Clinical Management. Int. J. Mol. Sci. 2023, 24, 11547.
Castillo, D.R.; Jeon, W.J.; Park, D.; Pham, B.; Yang, C.; Joung, B.; Moon, J.H.; Lee, J.; Chong, E.G.; Park, K.; Reeves, M.E.; Duerksen-Hughes, P.; Mirshahidi, H.R.; Mirshahidi, S. Comprehensive Review: Unveiling the Pro-Oncogenic Roles of IL-1ß and PD-1/PD-L1 in NSCLC Development and Targeting Their Pathways for Clinical Management. Int. J. Mol. Sci.2023, 24, 11547.
Castillo, D.R.; Jeon, W.J.; Park, D.; Pham, B.; Yang, C.; Joung, B.; Moon, J.H.; Lee, J.; Chong, E.G.; Park, K.; Reeves, M.E.; Duerksen-Hughes, P.; Mirshahidi, H.R.; Mirshahidi, S. Comprehensive Review: Unveiling the Pro-Oncogenic Roles of IL-1ß and PD-1/PD-L1 in NSCLC Development and Targeting Their Pathways for Clinical Management. Int. J. Mol. Sci. 2023, 24, 11547.
Abstract
In the past decade, targeted therapies for solid tumors, including non-small cell lung cancer (NSCLC), have advanced significantly, offering tailored treatment options for patients. However, individuals without targetable mutations pose a clinical challenge, as they may not respond to standard treatments like immune-checkpoint inhibitors (ICIs) and novel targeted therapies. While the mechanism of action of ICIs seems promising, the lack of a robust response limits their widespread use. Although the expression levels of programmed death ligand 1 (PD-L1) on tumor cells are used to predict ICI response, identifying new biomarkers, particularly those associated with the tumor microenvironment (TME), is crucial to address this unmet need. Recently, inflammatory cytokines such as interleukin-1 beta (IL-1β) have emerged as a key area of focus and hold significant potential implications for future clinical practice. Combinatorial approaches of IL-1β inhibitors and ICIs may provide a potential therapeutic modality for NSCLC patients without targetable mutations. In this review, we discuss the role of IL-1β in NSCLC, its involvement in inflammatory pathways, and explore its potential role in the treatment of NSCLC.
Keywords
interleukin-1 beta (IL-1β); immune-checkpoint inhibitors (ICIs); non-small cell lung cancer (NSCLC); programmed death ligand 1 (PD-L1); therapeutic resistance
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.